Biomarkers for the clinical evaluation of cognitive impairment

Biomarkers for the clinical evaluation of the cognitively impaired elderly, amyloid is not enough

Recently published in the journal Imaging in Medicine (June, 2012), Linda K. McEvoy and James B. Brewer argue that while incorporating biomarkers for assessing Alzheimer’s disease risk, including volumetric MRI done with NeuroQuant^®, can help in patient prognosis, tests for amyloid, if used in isolation, have potential for harm, as amyloid tests are clinically useful only when evidence suggests progressive cognitive decline or neurodegeneration. (Imaging in Medicine, June 2012, Vol. 4, No. 3 , Pages 343-357).